EP1743646A3 - Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels - Google Patents

Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels Download PDF

Info

Publication number
EP1743646A3
EP1743646A3 EP06016949A EP06016949A EP1743646A3 EP 1743646 A3 EP1743646 A3 EP 1743646A3 EP 06016949 A EP06016949 A EP 06016949A EP 06016949 A EP06016949 A EP 06016949A EP 1743646 A3 EP1743646 A3 EP 1743646A3
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
testosterone
methods
testosterone levels
serum testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06016949A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1743646A2 (en
Inventor
Doris HÜBLER
Jan-Peter Ingwersen
Sabine Fricke
Wilhelm Kuhnz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1743646(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of EP1743646A2 publication Critical patent/EP1743646A2/en
Publication of EP1743646A3 publication Critical patent/EP1743646A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
EP06016949A 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels Withdrawn EP1743646A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
EP04075804A EP1457208B9 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP04075804A Division EP1457208B9 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (2)

Publication Number Publication Date
EP1743646A2 EP1743646A2 (en) 2007-01-17
EP1743646A3 true EP1743646A3 (en) 2007-03-28

Family

ID=32748728

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06016949A Withdrawn EP1743646A3 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
EP04075804A Expired - Lifetime EP1457208B9 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04075804A Expired - Lifetime EP1457208B9 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Country Status (39)

Country Link
US (2) US7718640B2 (enrdf_load_html_response)
EP (2) EP1743646A3 (enrdf_load_html_response)
JP (1) JP4680891B2 (enrdf_load_html_response)
KR (2) KR20080096717A (enrdf_load_html_response)
CN (2) CN101884639A (enrdf_load_html_response)
AR (1) AR043603A1 (enrdf_load_html_response)
AT (1) ATE336251T1 (enrdf_load_html_response)
AU (1) AU2004218893B2 (enrdf_load_html_response)
BR (2) BRPI0400214A8 (enrdf_load_html_response)
CA (1) CA2518910C (enrdf_load_html_response)
CL (1) CL2004000527A1 (enrdf_load_html_response)
CO (1) CO5700724A2 (enrdf_load_html_response)
CR (1) CR7999A (enrdf_load_html_response)
CY (1) CY1105794T1 (enrdf_load_html_response)
DE (1) DE602004001893T2 (enrdf_load_html_response)
DK (1) DK1457208T3 (enrdf_load_html_response)
EA (1) EA011568B1 (enrdf_load_html_response)
EC (1) ECSP056095A (enrdf_load_html_response)
ES (1) ES2271772T3 (enrdf_load_html_response)
HR (1) HRP20050781B1 (enrdf_load_html_response)
IL (1) IL170473A (enrdf_load_html_response)
IS (1) IS2565B (enrdf_load_html_response)
JO (1) JO2505B1 (enrdf_load_html_response)
ME (2) ME00149B (enrdf_load_html_response)
MX (1) MXPA04002395A (enrdf_load_html_response)
NO (1) NO335179B1 (enrdf_load_html_response)
NZ (1) NZ542321A (enrdf_load_html_response)
PE (1) PE20041065A1 (enrdf_load_html_response)
PL (1) PL1457208T3 (enrdf_load_html_response)
PT (1) PT1457208E (enrdf_load_html_response)
RS (1) RS51537B (enrdf_load_html_response)
RU (2) RU2354381C2 (enrdf_load_html_response)
SA (1) SA04250040B1 (enrdf_load_html_response)
SI (1) SI1457208T1 (enrdf_load_html_response)
TW (1) TWI345976B (enrdf_load_html_response)
UA (1) UA82510C2 (enrdf_load_html_response)
UY (1) UY28231A1 (enrdf_load_html_response)
WO (1) WO2004080383A2 (enrdf_load_html_response)
ZA (2) ZA200508313B (enrdf_load_html_response)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
EP2985026B1 (en) * 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
EP4186545A1 (en) * 2012-04-06 2023-05-31 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
CN108096192A (zh) * 2012-05-09 2018-06-01 健康科学西部大学 前体脂质体睾酮制剂
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
FI3659647T3 (fi) * 2013-02-11 2024-03-28 Antares Pharma Inc Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
CN105744983B (zh) * 2013-08-12 2019-12-27 纳米医学系统公司 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) * 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
CA3107214A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
EP3893885A4 (en) * 2018-12-14 2022-09-07 Acerus Biopharma Inc. ACTIVE TESTOSTERONE ESTER DERIVATIVES, COMPOSITIONS AND USES THEREOF
EP4038147A4 (en) * 2019-10-03 2024-02-07 Caren Pharmaceuticals, Inc. COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4212863A (en) * 1977-10-29 1980-07-15 Akzo N.V. Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
WO1995012383A1 (fr) * 1993-10-30 1995-05-11 Zhejiang Medical University Solution injectable d'undecanoate de testosterone
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones
WO1998036770A1 (en) * 1997-02-24 1998-08-27 Cortendo Ab Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
WO2000059512A1 (en) * 1999-04-01 2000-10-12 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DK1035835T3 (da) * 1997-12-03 2003-12-08 Merck & Co Inc Langtidsvirkende injicerbare formuleringer indeholdende hydrogeneret castorolie
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
DK1087986T3 (da) 1998-06-19 2002-06-17 Akzo Nobel Nv Testosteronderivat
JP2003522795A (ja) * 2000-02-15 2003-07-29 シェーリング アクティエンゲゼルシャフト ノルエチステロンからなる男性用避妊製剤
CA2415349A1 (en) 2000-08-23 2002-02-28 Akzo Nobel N.V. Testosterone ester formulation for human use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
DE2548413A1 (de) * 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4212863A (en) * 1977-10-29 1980-07-15 Akzo N.V. Highly concentrated pharmaceutical formulations of steroids and processes for their preparation
WO1995012383A1 (fr) * 1993-10-30 1995-05-11 Zhejiang Medical University Solution injectable d'undecanoate de testosterone
WO1997040823A1 (en) * 1996-04-26 1997-11-06 R.P. Scherer Limited Oral pharmaceutical compositions containing sex hormones
WO1998036770A1 (en) * 1997-02-24 1998-08-27 Cortendo Ab Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
WO2000059512A1 (en) * 1999-04-01 2000-10-12 Akzo Nobel N.V. Formulation comprising testosteron undecanoate and castor oil

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"THE MERCK MANUAL OF DIAGNOSIS AND THERAPY", 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION,N.J. (U.S.A.), XP002305717 *
DATABASE WPI Section Ch Week 199524, Derwent World Patents Index; Class B01, AN 1995-185577, XP002264337 *

Also Published As

Publication number Publication date
ATE336251T1 (de) 2006-09-15
KR100882378B1 (ko) 2009-02-05
RU2007118196A (ru) 2008-11-27
ECSP056095A (es) 2006-03-01
CO5700724A2 (es) 2006-11-30
KR20080096717A (ko) 2008-10-31
RS20050702A (en) 2007-06-04
JP2006520377A (ja) 2006-09-07
PL1457208T3 (pl) 2007-01-31
NO20054711D0 (no) 2005-10-13
WO2004080383B1 (en) 2005-05-06
CA2518910A1 (en) 2004-09-23
CL2004000527A1 (es) 2005-02-18
WO2004080383A2 (en) 2004-09-23
EP1457208A1 (en) 2004-09-15
KR20050109561A (ko) 2005-11-21
TWI345976B (en) 2011-08-01
RU2005131724A (ru) 2006-05-10
BR122017008910A2 (enrdf_load_html_response) 2005-02-09
HRP20050781A2 (en) 2005-10-31
DK1457208T3 (da) 2006-12-11
BRPI0400214A (pt) 2005-02-09
NO335179B1 (no) 2014-10-13
UA82510C2 (uk) 2008-04-25
CN1761469B (zh) 2019-05-17
UY28231A1 (es) 2004-11-08
RS51537B (en) 2011-06-30
HK1069325A1 (en) 2005-05-20
JO2505B1 (en) 2009-10-05
CY1105794T1 (el) 2011-02-02
DE602004001893D1 (de) 2006-09-28
AU2004218893B2 (en) 2008-10-09
IS2565B (is) 2009-12-15
AU2004218893A1 (en) 2004-09-23
PT1457208E (pt) 2007-01-31
US8338395B2 (en) 2012-12-25
BR122017008910A8 (pt) 2023-05-09
WO2004080383A3 (en) 2005-03-31
EP1457208B9 (en) 2006-10-25
CA2518910C (en) 2009-09-08
ME00149B (me) 2010-06-10
EP1743646A2 (en) 2007-01-17
JP4680891B2 (ja) 2011-05-11
PE20041065A1 (es) 2005-02-24
US7718640B2 (en) 2010-05-18
SA04250040B1 (ar) 2008-01-07
US20090156564A1 (en) 2009-06-18
EA011568B1 (ru) 2009-04-28
US20050032762A1 (en) 2005-02-10
ZA200508313B (en) 2007-04-25
BRPI0400214A8 (pt) 2023-05-09
NZ542321A (en) 2008-05-30
IS8069A (is) 2005-10-12
RU2354381C2 (ru) 2009-05-10
MXPA04002395A (es) 2004-09-20
EP1457208B1 (en) 2006-08-16
MEP14508A (en) 2010-06-10
AR043603A1 (es) 2005-08-03
SI1457208T1 (sl) 2007-02-28
HRP20050781B1 (hr) 2015-04-10
ES2271772T3 (es) 2007-04-16
CN1761469A (zh) 2006-04-19
DE602004001893T2 (de) 2007-03-15
IL170473A (en) 2010-05-31
ZA200700046B (en) 2008-04-30
TW200511997A (en) 2005-04-01
NO20054711L (no) 2005-12-13
CR7999A (es) 2006-05-29
EA200501819A1 (ru) 2006-06-30
CN101884639A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
EP1743646A3 (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
JP2022180619A (ja) 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
CN1248738C (zh) 用于人的睾酮酯制剂
EP1772142A3 (en) Organic compounds
EP2335727A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
NZ514574A (en) Novel method of treatment
EP1790340A3 (en) Combination chemotherapy
EP1232757A4 (en) MEDICINE FOR DISEASES ASSOCIATED WITH LOSS OF BONE SUBSTANCE
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
IL210851A0 (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
WO2004034975A3 (en) Sustained release profile modification
JP2013534228A (ja) テストステロン欠乏症を治療するためのテストステロン溶液
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
AP1707A (en) Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same.
JP2005533036A5 (enrdf_load_html_response)
JP2003522795A5 (enrdf_load_html_response)
RU2004138811A (ru) Контрацептивная инъекция масляного раствора, вводимая самостоятельно
AU2004200067B2 (en) Method of Modulating the Basal Metabolic Rate of a Dieting Mammal By Administration of a Metabolic Modulating Agent to the Dieting Mammal
Handelsman Androgen delivery systems: testosterone pellet implants
MD1568F1 (en) Method of treatment of the burn disease in the burn shock period
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
WO2001007013A3 (en) Thioamide moiety-containing polymer drug conjugates
RU2006126632A (ru) Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060814

AC Divisional application: reference to earlier application

Ref document number: 1457208

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20070518

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1099230

Country of ref document: HK

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AXX Extension fees paid

Extension state: MK

Payment date: 20060814

Extension state: LV

Payment date: 20060814

Extension state: LT

Payment date: 20060814

Extension state: AL

Payment date: 20060814

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071129

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1099230

Country of ref document: HK